{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:05:23Z","timestamp":1792011923143,"version":"4.4.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sichuan Science and Technology Depart ment for Key Research and Development Program","award":["2019YFS0027"],"award-info":[{"award-number":["2019YFS0027"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec017\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Follicular lymphoma (FL) patients have achieved favorable long-term survival since the introduction of rituximab. However, the development of second primary malignancies (SPMs) indicates a poor survival prognosis for FL patients, and large-scale studies in this field remain limited. This study investigates the prognostic factors for FL patients in the rituximab era, as well as the clinical characteristics, risk factors, and prognosis for patients who developed SPMs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec018\">\n<jats:title>Methods<\/jats:title>\n<jats:p>From 2000 to 2020, a total of 33,104 patients with pathologically confirmed FL were identified within the Surveillance, Epidemiology, and End Results (SEER) database. Competing-risk regression analysis was used to assess prognostic factors for lymphoma-specific survival (LSS), risk factors for developing SPMs, and prognosis in FL patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec019\">\n<jats:title>Results<\/jats:title>\n<jats:p>Multivariate analysis identified age\u2009\u2265\u200940 years, Black race, unmarried status, non-urban residence, nodal lymphoma presentation, Grade 3 histology, advanced Ann Arbor stage, and B symptoms as independent adverse prognostic factors for both overall survival (OS) and LSS. Chemotherapy as initial treatment was associated with inferior LSS in FL patients. Protective factors for OS and LSS included female sex, higher income, diagnosis post-2005, diagnosis-to-treatment intervals &gt;1 month, and receipt of radiotherapy or surgery. SPMs correlated with reduced LSS risk in FL patients. Elevated SPM incidence among patients aged&gt;40years, and non-Hispanic ethnicity, while reduced SPM risks were observed in females, unmarried patients, those receiving non-radiotherapy initial treatment, Grade 3 cases, and patients diagnosed during 2015\u20132019. Notably, FL patients aged &gt;60 years, unmarried, and those diagnosed post-2010 demonstrated heightened OS risk following SPM development. Conversely, initial radiotherapy conferred protective effects against both OS and LSS in patients with SPMs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec020\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In this study, we conducted a large, population-based analysis across the United States to identify risk factors for the development of SPMs and to delineate prognostic indicators for FL patients in the context of rituximab therapy, along with the clinical characteristics, risk factors, and prognostic features associated with SPMs. These findings have translational implications for risk-adapted surveillance. Future studies should validate predictive models across diverse healthcare settings, elucidate molecular mechanisms of SPM pathogenesis in FL, and evaluate targeted screening interventions through prospective trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0324532","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T17:54:57Z","timestamp":1748454897000},"page":"e0324532","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk and prognosis of second primary malignancies in patients with follicular lymphoma in the era of rituximab: A population study based on the SEER database"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9521-368X","authenticated-orcid":true,"given":"Ying","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0549-4065","authenticated-orcid":true,"given":"Caigang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"1","key":"pone.0324532.ref001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"A Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"pone.0324532.ref002","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"E Jacobsen","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"pone.0324532.ref003","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","article-title":"Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma","volume":"98","author":"E Bachy","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"pone.0324532.ref004","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1182\/bloodadvances.2020002858","article-title":"Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35\/03 randomized trial","volume":"4","author":"AA Moccia","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"pone.0324532.ref005","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.16090","article-title":"Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era","volume":"187","author":"R Prusila","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"pone.0324532.ref006","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"I Fleury","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"pone.0324532.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(18)30155-8","article-title":"Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial","volume":"5","author":"T Watanabe","year":"2018","journal-title":"Lancet Haematol"},{"issue":"23","key":"pone.0324532.ref008","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"W Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0324532.ref009","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"BA Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"pone.0324532.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131158","article-title":"Radiotherapy compared to other strategies in the treatment of stage I\/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years","volume":"10","author":"DA Barzenje","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"pone.0324532.ref011","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/bloodadvances.2024014840","article-title":"Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35\/10 trial 10-year update","volume":"9","author":"E Kimby","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"pone.0324532.ref012","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1200\/JCO.2010.31.8311","article-title":"Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer","volume":"29","author":"LGT Morris","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0324532.ref013","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40164-024-00551-1","article-title":"Current and future therapies for follicular lymphoma","volume":"13","author":"PL Zinzani","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"pone.0324532.ref014","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"C Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0324532.ref015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3390\/jcm12041417","article-title":"Incidence trend of follicular lymphoma in Taiwan compared to Japan and Korea, 2001-2019","volume":"12","author":"L-C Chiu","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"pone.0324532.ref016","article-title":"Investigation of the incidence trend of follicular lymphoma from 2008 to 2017 in Taiwan and the United States using population-based data","volume":"17","author":"YC Su","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0324532.ref017","doi-asserted-by":"crossref","first-page":"14610","DOI":"10.1038\/s41598-020-71579-6","article-title":"Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation","volume":"10","author":"A Szumera-Cie\u0107kiewicz","year":"2020","journal-title":"Scient Rep"},{"issue":"3","key":"pone.0324532.ref018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.13271","article-title":"Diagnosis and management of follicular lymphoma: a comprehensive review","volume":"103","author":"R Dada","year":"2019","journal-title":"Eur J Haematol"},{"issue":"2","key":"pone.0324532.ref019","doi-asserted-by":"crossref","first-page":"2282652","DOI":"10.1080\/07853890.2023.2282652","article-title":"Incidence and mortality of second primary malignancies after lymphoma: a population-based analysis","volume":"55","author":"Y Liu","year":"2023","journal-title":"Ann Med"},{"key":"pone.0324532.ref020","article-title":"Clinical features, treatment options and outcomes in primary cutaneous B-cell lymphomas: a real-world, multicenter, retrospective study","author":"V Nikolaou","year":"2024","journal-title":"Int J Dermatol"},{"issue":"11","key":"pone.0324532.ref021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-021-00574-5","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018","volume":"11","author":"MAW Dinnessen","year":"2021","journal-title":"Blood cancer journal"},{"issue":"9","key":"pone.0324532.ref022","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2017.06.028","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a United States population-based study","volume":"17","author":"S Giri","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"pone.0324532.ref023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-023-00462-z","article-title":"Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter study","volume":"11","author":"J Zha","year":"2023","journal-title":"Biomark Res"},{"key":"pone.0324532.ref024","article-title":"Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses","author":"C Sun","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"pone.0324532.ref025","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/pon.5711","article-title":"Self-efficacy, psychological distress, and marital quality in young and middle-aged couples facing lymphoma: the mediating effect of dyadic coping","volume":"30","author":"H An","year":"2021","journal-title":"Psychooncology"},{"issue":"1","key":"pone.0324532.ref026","first-page":"691","article-title":"The association between radiotherapy and the prognosis of follicular lymphoma patients with different characteristics in the rituximab era: a cohort study based on Surveillance, Epidemiology and End Results","volume":"104","author":"L Li","year":"2025","journal-title":"Ann Hematol"},{"issue":"1","key":"pone.0324532.ref027","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"S Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"pone.0324532.ref028","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3389\/fimmu.2017.00828","article-title":"Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies","volume":"8","author":"G Genard","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0324532.ref029","doi-asserted-by":"crossref","first-page":"1876597","DOI":"10.1080\/2162402X.2021.1876597","article-title":"Anti-Ly6G binding and trafficking mediate positive neutrophil selection to unleash the anti-tumor efficacy of radiation therapy","volume":"10","author":"G Boivin","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"pone.0324532.ref030","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"H Liang","year":"2017","journal-title":"Nat Commun"},{"issue":"24","key":"pone.0324532.ref031","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.21037\/atm-22-6049","article-title":"Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review","volume":"10","author":"N-H Wang","year":"2022","journal-title":"Ann Transl Med"},{"issue":"3","key":"pone.0324532.ref032","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","article-title":"Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives","volume":"18","author":"M Oudkerk","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"pone.0324532.ref033","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1470-2045(24)00141-4","article-title":"Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based study","volume":"25","author":"M Sant","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0324532.ref034","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"CL Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"33","key":"pone.0324532.ref035","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"LM Morton","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"pone.0324532.ref036","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1007\/s00277-024-06022-1","article-title":"Is radiotherapy still the optimal initial choice for patients with early-stage low-grade follicular lymphoma in the modern era? A population-based study","volume":"103","author":"W Zheng","year":"2024","journal-title":"Ann Hematol"},{"issue":"11","key":"pone.0324532.ref037","first-page":"1558","article-title":"Prognostic value of interim PET\/CT in non-hodgkin lymphoma","volume":"148","author":"DL Guevara de","year":"2020","journal-title":"Rev Med Chil"},{"issue":"12","key":"pone.0324532.ref038","article-title":"The development of a prediction model based on random survival forest for the prognosis of non- Hodgkin lymphoma: a prospective cohort study in China","volume":"10","author":"X Li","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"pone.0324532.ref039","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.clml.2022.11.004","article-title":"Poly-lymphomatous syndrome with concurrent or sequential hodgkin and non-Hodgkin lymphoma","volume":"23","author":"M Iqbal","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T17:55:15Z","timestamp":1748454915000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324532"}},"subtitle":[],"editor":[{"given":"M Tanveer","family":"Hossain Parash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324532","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}